New hope for kidney disease: first human trial of PYC-003 begins
NCT ID NCT06714006
First seen Jan 05, 2026 · Last updated Jun 19, 2026 · Updated 23 times
Summary
This study is the first time a new drug called PYC-003 is being tested in humans. It is for people with a genetic kidney disease that causes cysts to grow and damage the kidneys. The trial will first test the drug in healthy volunteers to check safety, then in patients with the disease. The main goal is to see if the drug is safe and how the body processes it.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AUTOSOMAL DOMINANT POLYCYSTIC KIDNEY DISEASE (ADPKD) are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Concord Repatriation General Hospital
NOT_YET_RECRUITINGConcord, New South Wales, 2139, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Linear Clinical Research
RECRUITINGJoondalup, Western Australia, 6027, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
Contact
-
Liverpool Hospital, Clinic G-Reception 133, Level 1, Clinical Building, Burnside Drive
RECRUITINGLiverpool, New South Wales, 2170, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Mater Hospital Brisbane
RECRUITINGSouth Brisbane, Queensland, 4101, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Pacific Clinical Research Network Auckland
RECRUITINGTakapuna, Auckland, 0622, New Zealand
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
South Coast Renal, Brockway House, Level 1, Suite 8, 82-86 Queen Street,
RECRUITINGSouthport, Gold Coast, 4125, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
St Vincent's Hospital Melbourne
RECRUITINGFitzroy, Victoria, 3056, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Sunshine Hospital, Western Centre for Health Research and Education, Level 3, 176-190 Furlong Road
RECRUITINGSaint Albans, Victoria, 3021, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
-
Sydney Adventist Hospital
RECRUITINGWahroonga, New South Wales, 2076, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Contact
-
Westmead Hospital, Clinical Research Unit, Level 6, B Wing/Building, Hawkesbury Road
RECRUITINGWestmead, New South Wales, 2145, Australia
Contact
Contact Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
PYC-003 (a peptide attached to a synthetic DNA-like molecule)
What this could lead to
If this early trial shows the drug is safe, it could pave the way for a treatment that slows or stops kidney cysts from growing in people with ADPKD.
What could go wrong
This is a very early Phase 1 study, so the main goal is just to check safety. It is too soon to know if the drug will actually help the disease, and side effects are possible.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.